Investing.com -- Insmed Inc (NASDAQ:INSM) stock tumbled 17.2% in after-hours trading Wednesday after the biopharmaceutical company announced its Phase 2b BiRCh study of brensocatib in patients with ...

Shares of Insmed INSM lost nearly 20% in after-market trading on Wednesday after the company announced the failure of a ...

Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...

Glostrext Berhad (KLSE:GLXT) has had a great run on the share market with its stock up by a significant 13% over ...

Investing.com -- Arcus Biosciences (NYSE:RCUS) stock fell 8% after the clinical-stage biopharmaceutical company announced it would discontinue its Phase 3 STAR-221 cancer study due to futility.

People who regularly ate higher-fat cheese and cream had a lower risk of dementia over 25 years, while low-fat dairy and ...

The Motilal Oswal study reveals a cumulative wealth loss of ₹66,600 crore among the top 10 companies, with consumer sectors heavily impacted. Vodafone Idea and Rajesh Exports are notable wealth ...

Discover why Day One Biopharmaceuticals, Inc. is surging with Ojemda's growth, strategic deals, and key 2026 catalysts. Click ...

The U.S. stock market is having a terrific year. The benchmark S&P 500 ( ^GSPC +0.67%) is up 16% in 2025 despite economic ...

Shares of Arcus Biosciences, Inc. RCUS, a clinical-stage biopharmaceutical company, declined 14.4% following the announcement ...

Financial markets are often seen as chaotic and unpredictable. Every day, traders around the world buy shares and sell assets ...

The review also found that daily use of medical cannabis — especially inhaled or high-potency products — may increase the ...